Cancer Family
Sarcoma
CI-CAN-00000344SARExplore in graph →
634 active trials17 approved drugs182 evidence items
- NCIt
- C9118
- OncoTree
- SARCNOS
- DOID
- 1115
- MeSH
- D012509
- Other
- 1 more code
Loading cancer entity…
Cancer Family
CI-CAN-00000344SARExplore in graph →
Clinical trials
2,687 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06171282 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | unknown | Early Phase 1 | 9 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06117878 | Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma | unknown | Early Phase 1 | 12 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06114173 | Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma | unknown | Early Phase 1 | 15 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT04074564 | MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma | unknown | Early Phase 1 | 60 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05961111 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05851456 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT04864821 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | unknown | Early Phase 1 | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 0 | May 6, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Dec 14, 2023source: clinicaltrials